A new study published in JAMA Network Open indicates that pregnant women vaccinated against respiratory syncytial virus (RSV) can significantly reduce their newborns' risk of hospitalization due to the virus. The research reveals that maternal vaccination lowers the hospitalization odds by 68% and is 69% effective against severe lung infections caused by RSV. Lead researcher Dr. Anne-Marie Rick from the University of Pittsburgh School of Medicine emphasized the importance of these findings for families and healthcare systems. The FDA approved the maternal RSV vaccine, named Abrysvo, in 2023, marking a significant advancement in protecting newborns, as RSV is the leading cause of hospitalization among U.S. infants. The study analyzed health records of 274 infants under three months old hospitalized for respiratory illnesses during the 2023-24 and 2024-25 RSV seasons. Ongoing research will continue to assess the vaccine's effectiveness and track its impact on infants up to six months old, providing vital data for families, clinicians, and policymakers.